Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
J Eur Acad Dermatol Venereol ; 37(3): 573-580, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36331365

ABSTRACT

BACKGROUND: Rosacea is a common chronic inflammatory facial skin disorder. Standardized evaluation of the severity and extent of rosacea is important for baseline assessment and treatment effect. The currently used Investigator's Global Assessment (IGA) is unspecific and fails to consider subtypes/phenotypes of rosacea and area involvement. The Rosacea Area and Severity Index (RASI) was developed to give a more nuanced evaluation of rosacea features in four facial skin areas adjusted to the relative importance of each area of the face to obtain an overall severity score. OBJECTIVES: To validate RASI against the IGA and to assess the inter- and intraobserver reliability for RASI. METHODS: Sixteen dermatologists evaluated photographs of 60 adult patients with rosacea (3 photographs per patient, one from the front and one from each side). IGA and RASI scores were performed for interobserver reliability assessment. To determine intraobserver reliability, 14 dermatologists evaluated 10 other patients twice with at least 1 week interval. RESULTS: The IGA and RASI correlated well (Spearman correlation coefficient (SCC) = 0.75, 95% confidence interval (CI) = 0.72-0.78). Interobserver reliability was moderate for RASI and poor to moderate for IGA. Reliability was strongest for rhinophyma, followed by papules/pustules and erythema, and rather weak for telangiectasia. For area scores, interobserver reliability was strongest for cheeks, followed by nose, chin and forehead. We found a moderate-to-strong intraobserver agreement both for IGA and RASI. CONCLUSIONS: We have designed a new practical tool to examine clinical severity of rosacea. RASI proved simple and reliable in scoring clinical severity of rosacea with an agreement comparable to the currently used IGA although RASI will provide a more nuanced view of the current rosacea extent and severity. We suggest that RASI is used in the daily clinical setting as well as in clinical studies assessing the efficacy of rosacea therapies.


Subject(s)
Rosacea , Humans , Reproducibility of Results , Rosacea/diagnosis , Rosacea/drug therapy , Skin , Erythema , Immunoglobulin A , Severity of Illness Index
2.
Acta Derm Venereol ; 97(4): 426-432, 2017 Apr 06.
Article in English | MEDLINE | ID: mdl-27958611

ABSTRACT

Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.


Subject(s)
Dermatology/standards , Immunosuppressive Agents/administration & dosage , Methotrexate/administration & dosage , Psoriasis/drug therapy , Adult , Age Factors , Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/etiology , Child , Consensus , Denmark , Drug Dosage Calculations , Female , Humans , Immunosuppressive Agents/adverse effects , Liver Function Tests , Male , Methotrexate/adverse effects , Neoplasms/chemically induced , Neoplasms/diagnosis , Patient Safety , Pregnancy , Pregnancy Complications/chemically induced , Pregnancy Complications/diagnosis , Psoriasis/diagnosis , Psoriasis/immunology , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome
3.
Acta Derm Venereol ; 95(2): 173-6, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24941064

ABSTRACT

Risk of human papillomavirus (HPV) transmission during laser vaporisation of genital warts or loop electrode excision procedure is controversial. An oral rinse, a nasal swabs, history of HPV related diseases and data on HPV exposure were collected from 287 employees at departments of dermato-venerology and gynaecology in Denmark. A mucosal HPV type was found among 5.8% of employees with experience of laser treatment of genital warts as compared to 1.7% of those with no experience (p = 0.12). HPV prevalence was not higher in employees participating in electrosurgical treatment or cryotherapy of genital warts, or loop electrode excision procedure compared with those who did not. HPV 6 or 11 were not detected in any samples. Hand warts after the age of 24 years was more common among dermatology than among non-dermatology personnel (18% vs. 8.0%, p = 0.03). Mucosal HPV types are infrequent in the oral and nasal cavity of health care personnel, however, employees at departments of dermato-venereology are at risk of acquiring hand warts.


Subject(s)
Condylomata Acuminata/surgery , Electrosurgery , Laser Therapy/instrumentation , Lasers, Gas/therapeutic use , Mouth Diseases/epidemiology , Nose Diseases/epidemiology , Occupational Health , Papillomavirus Infections/epidemiology , Papillomavirus Infections/transmission , Uterine Cervical Dysplasia/surgery , Condylomata Acuminata/virology , Denmark , Electrosurgery/adverse effects , Female , Human Papillomavirus DNA Tests , Humans , Infectious Disease Transmission, Patient-to-Professional , Laser Therapy/adverse effects , Mouth Diseases/diagnosis , Mouth Diseases/virology , Mouth Mucosa/virology , Nasal Mucosa/virology , Nose Diseases/diagnosis , Nose Diseases/virology , Occupational Exposure , Papillomavirus Infections/diagnosis , Papillomavirus Infections/virology , Prevalence , Risk Assessment , Risk Factors , Uterine Cervical Dysplasia/virology
4.
Acta Derm Venereol ; 93(3): 309-13, 2013 May.
Article in English | MEDLINE | ID: mdl-22930352

ABSTRACT

A Danish-Swedish collaboration was established to identify and classify a Danish cohort of patients with epidermolytic ichthyosis, also known as epidermolytic hyperkeratosis. Patients were recruited from 5 dermatology departments in Denmark, and data were obtained using a structured questionnaire and a systematic examination together with photographs, histopathological descriptions and blood samples for mutational analysis. Sixteen patients from 12 families with generalized or naevoid epidermolytic ichthyosis and ichthyosis bullosa of Siemens were identified. Five families had mutations in K1 and 6 families had mutations in K10. Nine patients had been treated with systemic retinoids (etretinate, acitretin, isotretinoin or alitretinoin), but only 3 patients had acceptable treatment responses and chose to continue therapy. In conclusion epidermolytic ichthyosis is a rare disease with a prevalence of approximately 1 in 350,000 in Denmark and a high percentage of de novo mutations (75%). We identified 4 novel disease-causing mutations.


Subject(s)
Hyperkeratosis, Epidermolytic/genetics , Hyperkeratosis, Epidermolytic/pathology , Keratin-10/genetics , Keratin-1/genetics , Mutation , Skin/pathology , Adolescent , Adult , Aged , Child , Child, Preschool , DNA Mutational Analysis , Denmark/epidemiology , Female , Genetic Predisposition to Disease , Humans , Hyperkeratosis, Epidermolytic/drug therapy , Hyperkeratosis, Epidermolytic/epidemiology , Infant , Male , Pedigree , Phenotype , Prevalence , Retinoids/therapeutic use , Skin/drug effects , Surveys and Questionnaires , Treatment Outcome , Young Adult
6.
Int J Cancer ; 129(9): 2147-57, 2011 Nov 01.
Article in English | MEDLINE | ID: mdl-21190190

ABSTRACT

Vaccination against oncogenic human papillomavirus (HPV) types is one key intervention for cervical cancer prevention. This follow-up study assessed the persistence of the systemic and mucosal immune responses together with the safety profile of the HPV-16/18 AS04-adjuvanted vaccine administered to young women aged 10-25 years. Serum and cervicovaginal secretion (CVS) samples were collected at prespecified time-points during the 48-month follow-up period. Anti-HPV-16/18 antibody levels in serum and CVS were measured by enzyme-linked immunosorbent assay (ELISA). At Month 48, all subjects remained seropositive for serum anti-HPV-16 and -18 antibodies. As previously observed, anti-HPV-16 and -18 antibodies levels (ELISA Units/mL) were higher in subjects vaccinated at the age of 10-14 years (2862.2 and 940.8) compared to subjects vaccinated at the age of 15-25 years (1186.2 and 469.8). Moreover, anti-HPV-16 and -18 antibodies in CVS were still detectable for subjects aged 15-25 years (84.1% and 69.7%, respectively). There was a strong correlation between serum and CVS anti-HPV-16 and -18 antibodies levels (correlation coefficients = 0.84 and 0.90 at Month 48, respectively) supporting the hypothesis of transudation or exudation of serum immunoglobulin G antibodies through the cervical epithelium. The HPV-16/18 AS04-adjuvanted vaccine had a clinically acceptable safety profile. In conclusion, this follow-up study shows that the HPV-16/18 AS04-adjuvanted vaccine administered to preteen/adolescents girls and young women induces long-term systemic and mucosal immune response and has a clinically acceptable safety profile up to 4 years after the first vaccine dose.


Subject(s)
Human papillomavirus 16/immunology , Human papillomavirus 18/immunology , Papillomavirus Infections/immunology , Papillomavirus Vaccines/immunology , Adjuvants, Immunologic , Adolescent , Adult , Age Factors , Antibodies, Viral/blood , Antibodies, Viral/immunology , Child , Female , Follow-Up Studies , Humans , Immunity, Mucosal/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Papillomavirus Vaccines/administration & dosage , Papillomavirus Vaccines/adverse effects , Young Adult
8.
J Invest Dermatol ; 130(2): 438-43, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19890349

ABSTRACT

Infants born with autosomal recessive congenital ichthyosis (ARCI) are often encapsulated in a collodion membrane, which shows a lamellar or erythrodermic type of ichthyosis upon shedding. However, some babies show a nearly normal underlying skin after several weeks, a phenotype called "self-healing collodion baby" (SHCB). Mutations in two genes, TGM1 and ALOX12B, have previously been implicated in the etiology of SHCB, but the full genotypic spectrum remains to be determined. DNA sequencing in 11 Swedish and 4 Danish SHCB patients showed ALOX12B mutations in eight cases, ALOXE3 mutations in three cases, and TGM1 mutations in one case. In three patients, we could not find mutations in any of the known ARCI genes. In all cases, a spontaneous shedding of the collodion membrane occurred 2-4 weeks after birth. When re-examined at 2-37 years of age, the patients showed skin xerosis, a mild or focal scaling, palmar hyperlinearity with keratoderma, and a frequent appearance of red cheeks and anhidrosis. Thus, we propose replacing SHCB with the term "self-improving collodion ichthyosis" (SICI). In conclusion, ALOX12B mutations are the leading cause of SICI in Scandinavia, followed by ALOXE3 mutations, which have not been previously associated with this variant of ARCI.


Subject(s)
Arachidonate 12-Lipoxygenase/genetics , Ichthyosis/genetics , Lipoxygenase/genetics , Mutation , Transglutaminases/genetics , Adolescent , Adult , Child , Child, Preschool , Denmark , Female , Genotype , Humans , Ichthyosis/diagnosis , Male , Sweden
9.
Intensive Care Med ; 35(9): 1604-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19513693

ABSTRACT

PURPOSE: The underlying mechanisms for cerebral blood flow (CBF) abnormalities in acute bacterial meningitis (ABM) are largely unknown. Putative mediators include vasoactive peptides, e.g. calcitonin-gene related peptide (CGRP), vasoactive intestinal peptide (VIP), and endothelin-1 (ET-1), all of which may be affected by therapeutic interventions used in the intensive care unit. We measured arterial levels as well as the net cerebral flux of these peptides in patients with ABM, and in healthy volunteers undergoing interventions relevant to intensive care. METHODS: Seven patients with severe ABM and sepsis and fifteen healthy volunteers were included after informed consent. The net cerebral fluxes of vasoactive peptides were measured by the Kety-Schmidt technique in ABM patients (baseline study only), as well as in volunteers at baseline, during voluntary hyperventilation, after an intravenous injection of lipopolysaccharide (LPS), and during norepinephrine infusion. RESULTS: The arterial levels of CGRP, but not of VIP or ET-1, were elevated in patients with ABM, but no net cerebral flux was present. CGRP levels decreased during hyperventilation and after LPS injection. No net cerebral flux of VIP occurred in any group at any time. A cerebral efflux of ET-1, which occurred in volunteers at baseline, was neither present in volunteers after LPS injection nor in patients with ABM. CONCLUSION: The arterial concentration of the vasodilatory peptide, CGRP, but of neither VIP nor the vasoconstrictor ET-1, is elevated in patients with ABM and sepsis. A constitutive cerebral output of ET-1 appears to be present in healthy humans, but is abolished after LPS injection.


Subject(s)
Brain/blood supply , Meningitis, Bacterial/physiopathology , Vasoactive Intestinal Peptide/blood , Acute Disease , Adult , Aged , Calcitonin Gene-Related Peptide/blood , Critical Care , Endothelin-1 , Female , Humans , Lipopolysaccharides/blood , Male , Middle Aged
10.
J Adolesc Health ; 40(6): 564-71, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17531764

ABSTRACT

PURPOSE: In female individuals 15-25-years of age, the AS04-containing human papillomavirus (HPV)-16/18 vaccine is highly immunogenic and provides up to 100% protection against HPV-16/18 persistent infection and associated cervical lesions up to 4.5 years. Optimal cervical cancer prevention will require prophylactic vaccination against oncogenic HPV 16 and 18 before the onset of sexual activity in early adolescent girls. To establish the feasibility of vaccination in girls 10-14 years of age, we compared the immunogenicity and safety in early adolescent female individuals to those 15-25 years in whom vaccine efficacy has been demonstrated. METHODS: We enrolled 773 female participants aged 10-14 years and 15-25 years to receive the HPV-16/18 L1 VLP AS04 vaccine, which was administered at months 0, 1, and 6. Serum samples were collected at months 0 and 7; antibodies to HPV 16 and 18 VLPs were measured by enzyme-linked immunosorbent assay. Vaccine safety was assessed at 7 or 30 days after each dose; serious adverse events were recorded during the entire study period. RESULTS: Both age groups achieved 100% seroconversion for HPV 16 and 18. Participants in the group aged 10-14 years were not only noninferior to those 15-25 years in terms of HPV 16 and 18 seroconversion rates but also had approximately twice as high geometric mean titers. The vaccine was generally safe and well tolerated. CONCLUSIONS: These findings suggest that HPV vaccination during early adolescence is generally safe, well tolerated, and highly immunogenic. The observed higher antibody titers in the group 10-14 years of age are likely to result in longer antibody persistence. Overall, these data support the implementation of prophylactic HPV vaccination in this age group.


Subject(s)
Adolescent Health Services , Capsid Proteins/immunology , Oncogene Proteins, Viral/immunology , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Uterine Cervical Neoplasms/prevention & control , Viral Proteins/immunology , Adolescent , Adult , Age Factors , Antibodies, Viral , Child , Drug Evaluation , Enzyme-Linked Immunosorbent Assay , Female , Humans , Papillomavirus Infections/virology , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/virology
11.
Dan Med Bull ; 54(2): 99-111, 2007 May.
Article in English | MEDLINE | ID: mdl-17521526

ABSTRACT

Patients with FHF have a high risk of cerebral edema and intracranial hypertension. The pathophysiological background for this phenomenon is not completely settled, but alteration in CBF as well as cerebral metabolism seems to be of importance. Mechanical hyperventilation has a prompt effect on intracranial pressure. This effect is assumed to be caused by the hypocapnia induced alkalosis which produces vasoconstriction and thereby a decrease in CBF and cerebral blood volume. It has been stated that hyperventilation may be harmful to patients with FHF, but only few studies have addressed the effect of hyperventilation upon cerebral metabolism. In the present clinical studies we evaluated the effect of short-term mechanical hyperventilation upon cerebral circulation and metabolism in patients with FHF. Although global CBF was reduced in patients with FHF it tightly matched the cerebral oxidative requirements. Already in the early phase of FHF there was a prominent cerebral efflux of glutamine that could not be accounted for by cerebral ammonia uptake. Moderate hyperventilation reduced global CBF without compromising cerebral oxidative metabolism. In addition, moderate hyperventilation restored cerebral autoregulation in most patients with FHF, and normalised the cerebral nitrogen balance during short-term interventions. Studies of global and regional cerebral carbon dioxide reactivity showed normal global as well as regional cerebral carbon dioxide reactivity in almost all patients with FHF. However, cerebral perfusion in frontal brain regions as well as basal ganglia is low in FHF as compared to healthy subjects, which may make these regions at risk of hypoperfusion during pronounced hyperventilation. It is concluded that moderate short-term hyperventilation does not compromise cerebral oxidative metabolism. Recommendation of its prolonged use in FHF awaits further studies. Furthermore, the data of this thesis demonstrates that alterations in cerebral glutamine and ammonia metabolism precedes increases of CBF, which seems to be a phenomenon that takes place later during the disease course, i.e., immediately before intracranial pressure is rising.


Subject(s)
Cerebrovascular Circulation , Hyperventilation/etiology , Hyperventilation/physiopathology , Liver Failure, Acute/complications , Telencephalon/physiopathology , Acetaminophen/pharmacology , Ammonia/metabolism , Analgesics, Non-Narcotic/pharmacology , Animals , Carbon Dioxide/metabolism , Cerebrovascular Circulation/drug effects , Glutamine/metabolism , Hepatic Encephalopathy/complications , Hepatic Encephalopathy/physiopathology , Humans , Hyperventilation/metabolism , Oxygen/metabolism , Telencephalon/metabolism
12.
Ugeskr Laeger ; 168(44): 3827-8, 2006 Oct 30.
Article in Danish | MEDLINE | ID: mdl-17118245

ABSTRACT

More than two thirds of carcinomas of the uterine cervix are caused by human papilloma virus (HPV) types 16 and 18, and 90% of all genital warts are caused by HPV 6 and 11. In June 2006, the US Food and Drug Administration accepted the first prophylactic HPV vaccine against HPV 6, 11, 16 and 18 to be offered to girls and young women. This new vaccine is also now available in Denmark. Questions concerning economics, ethics, organization, and vaccine monitoring need to be discussed in connection with the establishment of a vaccine program. In addition, information to the general population as well as to health care providers and decision-makers should have been given a high priority.


Subject(s)
Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Uterine Cervical Neoplasms/prevention & control , Adolescent , Child , Denmark , Female , Humans , Immunization Programs/economics , Immunization Programs/organization & administration , Male , Papillomavirus Infections/complications , Papillomavirus Vaccines/supply & distribution , Uterine Cervical Neoplasms/virology
13.
Acta Derm Venereol ; 86(5): 425-8, 2006.
Article in English | MEDLINE | ID: mdl-16955188

ABSTRACT

Onychomycosis among diabetic patients has been reported in some studies to be of high prevalence. This study aimed to investigate the prevalence of onychomycosis among diabetic patients at a Danish University Hospital. Clinical and mycological examinations were performed on type 1 and 2 diabetic patients from in- and out-patient clinics. A total of 271 patients were enrolled, 72% males, mean age 61.3 years, 26% of the patients had diabetes type 1. The prevalence of toe nail onychomycosis (positive culture and/or microscopy) was 22% (n = 59) of which 55 cases were caused by dermatophytes (93%) and 4 cases by yeasts (7%). A correlation was found between onychomycosis and age (p =0.02) and severity of nail changes (p <0.001), respectively. However, no significant correlation was found to gender, type of diabetes, lower extremity arterial disease, neuropathy, toe amputation or oedema. Onychomycosis occurred with a high prevalence in diabetic patients, especially among older patients and those with severe nail changes.


Subject(s)
Foot Dermatoses/epidemiology , Adult , Aged , Aged, 80 and over , Denmark/epidemiology , Diabetic Foot/epidemiology , Female , Foot Dermatoses/pathology , Humans , Male , Middle Aged , Onychomycosis/epidemiology , Onychomycosis/pathology , Prevalence
14.
Clin Auton Res ; 16(3): 208-16, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16572350

ABSTRACT

Cerebral blood flow autoregulation is lost in patients with severe liver cirrhosis. The cause of this is unknown. We determined whether autonomic dysfunction was related to impaired cerebral autoregulation in patients with cirrhosis. Fourteen patients with liver cirrhosis and 11 healthy volunteers were recruited. Autonomic function was assessed in response to deep breathing, head-up tilt and during 24-h Holter monitoring. Cerebral autoregulation was assessed by determining the change in mean cerebral blood flow velocity (MCAVm, transcranial Doppler) during an increase in blood pressure induced by norepinephrine infusion (NE). The severity of liver disease was assessed using the Child-Pugh scale (class A, mild; class B, moderate; class C, severe liver dysfunction).NE increased blood pressure similarly in the controls (27 (24-32) mmHg) and patients with the most severe liver cirrhosis (Child-Pugh C, 31 (26-44) mmHg, p=0.405 Mann-Whitney). However, the increase in MCAVm was greater in cirrhosis patients compared to the controls (Child-Pugh C, 26 (24-39) %; controls, 3 (-1.3 to 3) %; respectively, p=0.016, Mann-Whitney). HRV during deep breathing was reduced in the cirrhosis patients (Child-Pugh C, 6.0+/-2.0 bpm) compared to the controls (21.7+/-2.2 bpm, p=0.001, Tukey' test). Systolic blood pressure fell during head-up tilt only in patients with severe cirrhosis. Our results imply that cerebral autoregulation was impaired in the most severe cases of liver cirrhosis, and that those with impaired cerebral autoregulation also had severe parasympathetic and sympathetic autonomic dysfunction. Furthermore, the degree of liver dysfunction was associated with increasing severity of autonomic dysfunction. Although this association is not necessarily causal, we postulate that the loss of sympathetic innervation to the cerebral resistance vessels may contribute to the impairment of cerebral autoregulation in patients with end-stage liver disease.


Subject(s)
Autonomic Nervous System Diseases/diagnosis , Autonomic Nervous System Diseases/physiopathology , Autonomic Pathways/physiopathology , Cerebrovascular Circulation , Liver Cirrhosis/physiopathology , Adult , Autonomic Nervous System Diseases/complications , Autonomic Pathways/drug effects , Blood Flow Velocity/drug effects , Blood Pressure/drug effects , Cerebrovascular Circulation/drug effects , Electrocardiography, Ambulatory , Female , Heart Function Tests , Humans , Liver Cirrhosis/complications , Male , Middle Aged , Norepinephrine , Reference Values , Tilt-Table Test , Ultrasonography, Doppler, Transcranial , Vasoconstrictor Agents
16.
Liver Transpl ; 9(12): 1244-52, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14625823

ABSTRACT

Hyperammonemia and hyperventilation are consistent findings in patients with fulminant hepatic failure (FHF), which may interfere with cerebral glucose and oxygen metabolism. The aim of the present study is to evaluate whether cerebral oxidative metabolism is preserved early in the course of FHF and whether hyperventilation has an influence on this. We included 16 patients with FHF, 5 patients with cirrhosis of the liver, and 8 healthy subjects. Concomitant blood sampling from an arterial catheter and a catheter in the jugular bulb and measurement of cerebral blood flow by the xenon 133 wash-out technique allowed calculation of cerebral uptake of glucose (CMRgluc) and oxygen (CMRO2). Both CMRgluc and CMRO2 were reduced in patients with FHF compared with those with cirrhosis and healthy subjects, i.e., 11.8 +/- 2.7 v 18.3 +/- 5.5 and 28.5 +/- 6.6 micromol/100 g/min (P <.05) and 86 +/- 18 v 164 +/- 42 and 174 +/- 27 micromol/100 g/min (P <.05). Arteriovenous difference in oxygen and oxygen-glucose index were normal in patients with FHF. Institution of mechanical hyperventilation did not affect glucose and oxygen uptake and hyperventilation did not affect lactate-pyruvate ratio or lactate-oxygen index. In conclusion, we found that cerebral glucose and oxygen consumption are proportionally decreased in patients with FHF investigated before clinical signs of cerebral edema. Our data suggest that cerebral oxidative metabolism is retained at this stage of the disease without being compromised by hyperventilation.


Subject(s)
Brain/metabolism , Liver Failure/metabolism , Oxygen/metabolism , Acetoacetates/metabolism , Humans , Lactic Acid/metabolism , Liver Cirrhosis/metabolism , Liver Failure/enzymology , Oxygen Consumption , Pyruvic Acid/metabolism
17.
J Cereb Blood Flow Metab ; 22(10): 1262-70, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12368665

ABSTRACT

The proinflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha), has been suggested to mediate septic encephalopathy through an effect on cerebral blood flow (CBF) and metabolism. The effect of an intravenous bolus of endotoxin on global CBF, metabolism, and net flux of cytokines and catecholamines was investigated in eight healthy young volunteers. Cerebral blood flow was measured by the Kety-Schmidt technique at baseline (during normocapnia and voluntary hyperventilation for calculation of subject-specific cerebrovascular CO reactivity), and 90 minutes after an intravenous bolus of a reference endotoxin. Arterial TNF-alpha peaked at 90 minutes, coinciding with a peak in subjective symptoms. At this time, CBF and Paco were significantly reduced compared to baseline; the CBF decrease was readily explained by hypocapnia. The cerebral metabolic rate of oxygen remained unchanged, and the net cerebral flux of TNF-alpha, interleukin (IL)-1beta, and IL-6 did not differ significantly from zero. Thus, high circulating levels of TNF-alpha during human endotoxemia do not induce a direct reduction in cerebral oxidative metabolism.


Subject(s)
Blood Flow Velocity/physiology , Brain Diseases/physiopathology , Cerebrovascular Circulation/physiology , Endotoxemia/physiopathology , Oxygen Consumption/physiology , Adult , Brain Diseases/blood , Brain Diseases/metabolism , Cytokines/blood , Electrolytes/blood , Endotoxemia/metabolism , Endotoxins/toxicity , Female , Hemoglobins/metabolism , Humans , Inflammation/blood , Inflammation/chemically induced , Inflammation/physiopathology , Interleukin-1/blood , Interleukin-6/blood , Kidney Function Tests , Leukocyte Count , Liver Function Tests , Male , Reference Values , Time Factors , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...